aggregation and smooth muscle proliferation. Treprostinil is currently marketed by United Therapeutics in different dosage forms to alleviate the symptoms, maintain or improve functional class, delay disease progression, and improve quality of life...
Medicines Discovery Catapult (MDC) and Crown Bioscience have formed a strategic global collaboration to deliver an integrated translational biology platform for innovators developing radiopharmaceuticals. Radiopharmaceuticals are a growing class...
Marius Pharmaceuticals, Inc. announced a collaboration with Hims & Hers™, one of the largest digital health platforms for men, to make KYZATREX®, an FDA-approved oral testosterone replacement therapy for adult men with low or no testosterone...
Waldencast plc a global multi-brand beauty and wellness platform, announced that the U.S. Food and Drug Administration (“FDA”) has approved Obagi® saypha® MagIQ™ injectable hyaluronic acid (“HA”) gel, the first product in the Obagi® saypha®...
Avadel Pharmaceuticals plc a biopharmaceutical company focused on transforming medicines to transform lives, today announced that new data supporting the use of LUMRYZ as a narcolepsy treatment will be presented in one oral presentation and 16...
the recent approval of IBTROZI in the U.S., which has added an important new option for a range of patients with this form of lung cancer, regardless of prior exposure to tyrosine kinase inhibitor therapy.” “Disease progression remains one of the...
provide further evidence of the potential role that ifinatamab deruxtecan could play in treating this aggressive form of lung cancer.” The safety profile observed in IDeate-Lung01 was consistent with that seen for ifinatamab deruxtecan in the phase...
Precision BioSciences, Inc. a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, announced that it will be issued U.S. Patent No....
Global Head of Swine at Boehringer Ingelheim. “We’ll continue to closely monitor PCV2 and other diseases impacting pig performance to help producers stay ahead of emerging risks.” A vaccine that provides broad cross-protection is essential for...
of the most advanced capsule filling and inhalation drug development capabilities in the industry. Innovative machine platforms and packaging systems ensure that Experic’s customers benefit from flexible, scalable solutions tailored to their needs....
StemSight, Rinri Therapeutics, and Novadip. Each company intends to integrate Mytos’ iDEM automated cell manufacturing platform to scale the production of diverse cell types for therapeutic use, highlighting the platform’s versatility to create...
SC administration. The current injection time for each LEQEMBI IQLIK autoinjector takes approximately 15 seconds. The SC formulation also has the potential to reduce healthcare resources associated with IV maintenance dosing, such as preparation...
have served a diverse set of programmes, consistently delivering value based on our quality and responsiveness. For more information please visit, https://www.sailife.com/
undersøger en unik triple-therapy (fosfomycin, metronidazol og GM-CSF), som gives direkte i bughulen under operationen. Formålet med studiet er at dokumentere, at RNX-011 kan reducere antallet af alvorlige postoperative komplikationer, såsom...
CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the treatment of severe diseases, today announced the successful treatment of the first sickle...
updates. Dr. Michael Yu, Founder, Chairman of the Board and CEO of Innovent, stated: "We delivered an outstanding performance in the first half of 2025, driven by the comprehensive acceleration of our dual-engine growth model and global innovation...
aligns perfectly with our mission to provide patients with the essential medicines they need." IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS GVOKE VialDx is contraindicated in patients with: Pheochromocytoma, because of the risk of substantial...
of our next-generation IO therapy, IBI363 (PD-1/IL-2α-bias). If successful, this trial could bring a potentially transformative treatment to patients with squamous NSCLC worldwide, who currently have limited options after checkpoint inhibitor...
baseline to Week 8. "Completing enrollment in CYPRESS marks a major step toward bringing this potentially transformative therapy to patients with symptomatic nOH due to MSA – an underserved patient population in dire need for a new, effective and...
in the lung arteries. VTB-10 is a first-in-class drug candidate developed using VASTHERA’s proprietary Redoxizyme™ platform. VASTHERA identified a deficiency of the enzyme peroxiredoxin (PRX) in PAH lesions and developed VTB-10, a small molecule...
